Foxp3
+ regulatory T (Treg) cells maintain immune homeostasis by limiting different types of inflammatory responses. Here, we report that miR-146a, one of the miRNAs prevalently expressed in Treg cells, is critical for their suppressor function. The deficiency of miR-146a in Treg cells resulted in a breakdown of immunological tolerance manifested in fatal IFNg-dependent immune-mediated lesions in a variety of organs. This was likely due to augmented expression and activation of signal transducer and activator transcription 1 (Stat1), a direct target of miR-146a. Likewise, heightened Stat1 activation in Treg cells subjected to a selective ablation of SOCS1, a key negative regulator of Stat1 phosphorylation downstream of the IFNg receptor, was associated with analogous Th1-mediated pathology. Our results suggest that specific aspects of Treg suppressor function are controlled by a single miRNA and that an optimal range of Stat1 activation is important for Treg-mediated control of Th1 responses and associated autoimmunity.
INTRODUCTION
A variety of pathologies are caused by the immune responses to ''self'' and environmental nonmicrobial antigens, to microbial antigens derived from commensal microorganisms, and to infectious agents. Regulatory T (Treg) cells limit ''collateral damage'' resulting from protective immunity to infection and suppress sterile inflammation as well as unwanted immune responses to ''self'' and allergens (Belkaid and Tarbell, 2009; Lu and Rudensky, 2009; Sakaguchi, 2005) . Suppressive function of Treg cells is indispensable for the immune homeostasis and survival of higher organisms; Treg cell ablation in healthy adult mice leads to a fatal, aggressive lympho-and myeloproliferative autoimmune syndrome (Kim et al., 2007) . X chromosome-encoded transcription factor Foxp3 plays a pivotal role in differentiation, homeostasis, and function of Treg cells. Foxp3 loss-of-function mutations cause systemic immune-mediated lesions similar to those observed upon chronic Treg cell ablation (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003) . Analyses of T cells expressing GFP-tagged null and functional Foxp3 alleles and genome-wide analysis of Foxp3 binding genes showed that Foxp3 directly or indirectly controls several thousand genes in Treg cells (Fontenot et al., 2005; Gavin et al., 2007; Lin et al., 2007; Zheng et al., 2007; Marson et al., 2007) . These studies also revealed that a number of genes constitutively up-or downregulated in Treg cells in a Foxp3-dependent manner undergo corresponding changes, albeit transient and less prominent, in activated effector T cells. This sizable cluster of ''Foxp3-amplified'' genes includes those serving as hallmarks of Treg cells (CTLA4, CD25, and GITR) and playing important functional roles in their homeostasis and function Lin et al., 2007; Zheng et al., 2007; Marson et al., 2007) . These results suggested that Foxp3 acts in an ''opportunistic'' manner by amplifying and stabilizing expression of genes beneficial to Treg cell function.
In addition to coding genes, the ''Foxp3-amplified'' cluster also includes several small noncoding RNA known as microRNAs (miRNAs) (Cobb et al., 2006) . Notably, miRNAs serve as important regulators of Treg cell homeostasis and function in both basal and inflammatory settings (Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008) . Ablation of miRNA precursor-processing enzyme Dicer in Treg cells results in a reduction in their numbers and suppressive capacity in healthy mice harboring both Dicer-deficient and -sufficient Treg cells and a complete loss of suppressor function in diseased mice lacking wild-type Treg cells (Liston et al., 2008) . Consequently, the generalized depletion of miRNAs in Treg cells leads to a fatal early-onset autoimmune pathology indistinguishable from that in Foxp3 mutant mice devoid of Treg cells (Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008) . These results and the description of a subset of miRNAs differentially expressed in regulatory versus effector T cells (Cobb et al., 2006 ) raised a question as to how individual miRNAs present in increased amounts in Treg cells contribute to distinct aspects of their homeostasis and function. In this regard, miR-155, a well-known onco-miR (cancer-associated micro-RNA), is constitutively expressed in high amounts in Treg cells in a Foxp3-dependent manner, whereas T cells lacking Foxp3, B cells, and myeloid cells transiently upregulate miR-155 upon activation (Androulidaki et al., 2009; O'Connell et al., 2007; Thai et al., 2007) . Our previous studies showed that miR-155 confers heightened responsiveness of Treg cells to their key survival and growth factor, IL-2, thereby maintaining their numbers in a competitive environment. However, miR-155 is largely dispensable for Treg suppressor function .
Like miR-155, miR-146a is highly expressed in Treg cells and is induced upon activation of effector T cells and myeloid cells. In the latter, miR-146a acts as a negative feedback regulator to limit TRAF6 and IRAK1/2-mediated signaling in inflammatory settings (Hou et al., 2009; Taganov et al., 2006) , whereas in activated human T cells, miR-146a has been suggested to oppose apoptosis and IL-2 production (Curtale et al., 2010) . Thus, we explored a role for miR-146a in Treg cells and found that this microRNA is essential for the ability of Treg cells to restrain IFNg-mediated pathogenic Th1 responses and associated inflammation. In Treg cells, miR-146a-mediated downregulation of Stat1, a key transcription factor required for Th1 effector cell differentiation, was necessary for Treg ability to suppress Th1 responses. Furthermore, relieving negative regulation of Stat1 activation in Treg cells using an alternative genetic approach resulted in a breakdown of immune homeostasis similar to that observed in mice harboring miR-146a-deficient Treg cells. Thus, our results suggest that a specific miRNA overrepresented in Treg cells ensures their suppressor function by maintaining an optimal threshold of cytokine receptor-dependent activation of transcription factors crucial for a particular type of immune response.
RESULTS

Elevated miR-146a Expression in Treg Cells
To identify miRNAs essential for controlling Treg cell function, we considered miRNAs differentially expressed between Foxp3 + Treg cells and Foxp3 -non-Treg CD4 + T cells (Cobb et al., 2006 ; data not shown). Among miRNA overrepresented in Treg cells, miR-146 was particularly prominent. This miRNA has been implicated in negative regulation of immune cell function, specifically in negative feedback regulation of myeloid cell activation (Taganov et al., 2006) . To study the role of miR-146 in Treg cells, we first sought to confirm the high amounts of miR-146 in Treg cells. Since mature miR-146a and miR146b sequences differ by two nucleotides, it was difficult to distinguish whether miR-146a or miR-146b or both are present in increased amounts in Treg cells. To address this issue, we performed stem-loop based Taqman real-time RT-PCR assay, which allowed us to distinguish miRNAs within the same family (Chen et al., 2005) . As shown in Figure S1A (available online), the miR-146a expression in CD4 + CD25 + Treg cells was sharply augmented in comparison to that in CD4  + CD25   -CD62L hi -naive T cells, while miR-146b expression was much lower. Analysis of Treg and non-Treg cell subsets isolated from miR-146a-deficient mice suggested that the small increase in miR-146b signal in Treg cells was likely due to miR-146a expression since miR-146b expression could no longer be observed in miR-146a-deficient Treg cells ( Figure S1A ). In support of this notion, examination of primary miRNA transcripts demonstrated that pri-miR-146a but not pri-miR-146b was elevated in Treg cells compared with naive T cells ( Figure S1B ). Thus, miR-146a, but not miR-146b, was highly upregulated in Treg cells.
miR-146a Deficiency Resulted in Increased Numbers but Impaired Function of Treg Cells
To assess a role for miR-146a in Treg cells, we examined Foxp3 + Treg cell subsets in the thymus and in the peripheral lymphoid organs of miR-146a-deficient mice. These mice develop severe lympho-and myeloproliferative syndrome at 6 months of age (M.P.B., K.D.T. and D.B., unpublished data). Therefore, we analyzed miR-146a-deficient and littermate control mice at 6-8 weeks of age prior to development of any clinical signs of autoimmune or inflammatory disease and found comparable sizes of different thymocyte and peripheral lymphoid and myeloid cell subsets (Figures S1C-S1F; data not shown). Moreover, T cell activation status was also similar to that observed in the wild-type (WT) littermates ( Figure S1I ; data not shown). In contrast to a reduction in Treg cell numbers observed in mice lacking miR-155 ), miR-146a-deficient mice contained significantly increased numbers of Foxp3 + Treg cells in the periphery, but not in the thymus (Figures S1G and S1H) . Consistent with its increased size, the miR-146a-deficient Treg cell subset exhibited heightened proliferative activity reflected in augmented expression of Ki67 and a modest increase in several activation markers ( Figure S1J ; data not shown).
As miR-146a is an important negative regulator of myeloid cell responses to cytokines and Toll-like receptor (TLR) ligands, it was possible that increased miR-146a-deficient Treg cell numbers were due to a heightened activation status of dendritic cell (DC), but not a cell-intrinsic effect of miR-146a deficiency. It was also possible that altered immune effector function in Mirn146a À/À mice masked potential defects in miR-146a-deficient Treg cell-mediated suppression. To explore these possibilities we performed a series of bone marrow (BM) transfer studies ( Figure 1A Figure 1B ). Histological examination of Mirn146a À/À /Foxp3KO chimeras 6-7 weeks after transfer showed massive lymphocyte activation and tissue infiltration in the lung, liver, and skin similar to that observed in mice harboring Dicer-deficient Treg cells (Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008) . In contrast, there were no clinical or histological signs of immune-mediated lesions in control Mirn146a À/À /B6 chimeras where both miR-146a-deficient and -sufficient Treg cells were present ( Figure S2 Despite their increased numbers, miR-146a-deficient Treg cells were unable to restrain activation of miR-146a-sufficient effector T cells, which was exhibited by high proliferative activity, an increased CD62L low cell subset, and high levels of the activation markers ICOS and CTLA4 ( Figure 1H ). In agreement with the histolopathology data and lack of clinical signs of disease, flow cytometric analysis of control Mirn-146a
showed that both miR-146a-sufficient and -deficient effector T cells were kept in check by the miR-146a-sufficient Treg cells present in these mice ( Figure 1I ). These results suggested an indispensable role of miR-146a in Treg cell-mediated immunological tolerance.
miR-146a Deficiency in Treg Cells Resulted in Dysregulated IFNg Responses
To identify the underlying mechanisms responsible for early fatal immune-mediated disease observed in Mirn146a
/Foxp3KO chimeras, we first sought to examine whether miR-146a deficiency results in a general impairment of Treg suppression function in inflammatory settings similar to Dicer deficiency in Treg cells (Liston et al., 2008 (Figures 2A and 2B ). These results suggested that, unlike Dicer deficiency, lack of miR-146a did not diminish the overall suppressor capacity of Treg cells reflected by an in vitro suppression assay. Instead, a particular aspect of Treg suppressor function was likely impaired in the absence of miR-146a.
As mentioned earlier, miR-146a functions as a negative regulator of TLR/IL-1 signaling pathway by targeting TRAF6 and IRAK1/2 (Taganov et al., 2006; Hou et al., 2009) . A recent study demonstrated that IL-1 stimulation results in IL-17 production in CD4 + T cells including Foxp3 + Treg cells (Chung et al., 2009 ). Moreover, a critical role of IRAK1 in promoting Th17 differentiation at the expense of TGFb-dependent generation of peripheral Foxp3 + Treg cells suggested a possibility that the lack of miR146a might lead to heightened Th17 responses, which cause the fatal autoimmunity in Mirn146a À/À /Foxp3KO chimeras (Maitra et al., 2009) . Indeed, in agreement with previous studies we found increased levels of TRAF6 and IRAK1 in Treg and nonTreg T cells ( Figure S1K ). However, we did not observe any change in either Foxp3 induction or Th17 differentiation in vitro in the presence or absence of miR-146a ( Figure S1L ). More importantly, Th17 cell numbers were similar in Mirn146a À/À / Foxp3KO and control Mirn146a +/+ /Foxp3KO and Mirn146a À/À / B6 mice (data not shown). Further analysis of cytokine production showed that the loss of miR-146a in Treg cells resulted in increased production of the proinflammatory Th1 cytokine IFNg by both miR-146a-deficient and -sufficient CD4 and CD8 T cells, whereas production of IL-4, IL-5, and IL-17 was unaffected ( Figure 2C ; data not shown). This increase was not observed in the presence of miR-146a-sufficient Treg cells in Mirn146a Figure 2F ; data not shown). The selective dysregulation of Th1 responses in the presence of miR-146a-deficient Treg cells was in contrast to sharply increased production of multiple cytokines (IL-2, IL-4, IL-5, IL-17, and IFNg) in the presence of Dicer-deficient Treg cells (Liston et al., 2008) . /B6 BM (I) 6-7 weeks after BM transfer. Data are representative of three independent experiments (n = 11-13); values represent the mean ± standard deviation (SD), *p < 0.05. See also Figure S1 and Figure S2 .
Consistent with these findings, purified miR-146a-deficient Treg cells adoptively transferred together with Foxp3KO CD4 + effector T cells into lymphopenic recipients failed to restrain Th1 responses ( Figure S3 ).
In addition to a marked increase in IFNg production in miR146a-sufficient and -deficient effector T cells, a sizable proportion of miR-146a-deficient Foxp3 + Treg cells produced IFNg in
IFNg and other effector cytokines by Treg cells is kept in check by Foxp3 likely as a ''safety'' feature, since Treg cells express TCR with an increased reactivity against ''self'' antigens (Hsieh et al., 2006) . Loss of Foxp3 in Treg cells resulted in the acquisition of the ability to produce proinflammatory cytokines, and cause tissue lesions in the absence of functional Treg cells (Williams and Rudensky, 2007; Zhou et al., 2009) . Thus, our current observations suggested that in addition to Foxp3, miR146a prevents acquisition of Th1-like properties by Treg cells, i.e., restrains production of the proinflammatory cytokine IFNg by Treg cells.
IFNg Blockade Prevents Autoimmune Disease in Mice Harboring miR-146a-Deficient Treg Cells
Next, we examined whether the augmented IFNg response was responsible for the autoimmune disease observed in Mirn146a À/À /Foxp3KO chimeric mice. To address this question, we neutralized the IFNg activity by treating mice with IFNg blocking antibody starting 3 weeks after BM transfer ( Figure 3A ). IFNg blockade did not affect the increases in miR-146a-deficient Treg cell numbers ( Figure 3B ); however, it rescued the disease observed in their presence. At the time of analysis, treated Mirn146a À/À /Foxp3KO mice were disease free and phenotypically indistinguishable from control Mirn146a +/+ /Foxp3KO mice ( Figure 3C ; data not shown). In contrast, control IgG treated Mirn146a À/À /Foxp3KO mice developed severe clinical signs of immune-mediated disease and tissue inflammation ( Figure 3C ; data not shown). The effectiveness of IFNg blockade was also manifested in normalization of the number of T cells expressing CXCR3, a Th1-specific chemokine receptor (Nakajima et al., 2002; Barbi et al., 2007) , in IFNg antibody-treated mice, whereas, in IgG-treated animals, CXCR3 expression on effector and Treg cells remained high ( Figure 3C ; data not shown). Importantly, antibody-mediated neutralization of IFNg and rescue of Th1-mediated disease in Mirn146a À/À /Foxp3KO mice were not associated with measurable increases in IL-4 or IL-17 (Figure 3D ). These results suggested that miR-146a-deficient Treg cells were able to restrain Th2 and Th17, but not Th1 responses and that immune-mediated lesions observed in the presence of miR-146a-deficient Treg cells were IFNg dependent. Since an increase in numbers of miR-146a-deficient Treg cells was unaffected by IFNg neutralization, these experiments also imply that Treg cell homeostasis and suppressor function are likely controlled by miR-146a via distinct molecular mechanisms.
miR-146a Regulates Stat1 in Treg Cells
Next, we sought to explore molecular mechanisms underlying miR-146a-dependent Treg cell-mediated Th1 regulation. In addition to the aforementioned miR-146a targets, TRAF6 and IRAK1, a recent study has suggested that Stat1 is a miR-146a target in human PBMCs (Tang et al., 2009 ). Since Stat1 is a key transcription factor downstream of IFNg receptor signaling, it was possible that Stat1 expression in miR-146a-deficient Treg cells was increased and could account for the IFNg-/Th1-dependent immune-mediated lesions observed in Mirn146a
À/À /Foxp3KO chimeras. However, unlike the 3 0 UTR of the human Stat1 gene, which contains a perfect match with the miR-146a seed sequence, no canonical target sequence was found in the mouse Stat1 gene. Nevertheless, a highly conserved sequence with partial complementary to miR-146a was present in the mouse Stat1 3 0 UTR ( Figure 4A ). Although computational algorithms relying on miRNA seed sequence analysis failed to identify mouse Stat1 as a miR-146a putative target, it was recently shown that some microRNAs, like miR-24, control multiple genes in the absence of canonical target seed sequences (Lal et al., 2009 ). Thus, it was possible that miR-146a might recognize mouse Stat1 through ''seedless'' yet conserved complementary sequences. Indeed, transfection of mouse Stat1 3 0 UTR-containing luciferase reporter into miR146a-sufficient, but not miR-146a-deficient T cells showed repression of reporter activity, which was abolished upon mutagenesis of the putative miR-146a binding site ( Figure 4B ). Moreover, miR-146a overexpression in HEK293 cells reduced luciferase reporter activity (data not shown). Finally, we found an $3-to 4-fold increase in total Stat1 protein in both Treg and non-Treg cells lacking miR-146a. Together, these results suggested mouse Stat1 serves as a target of miR-146a in mouse T cells ( Figure 4C ). Levels of phosphorylated Stat1 were also markedly increased in miR-146a-deficient cells. Consistent with the rescue from disease, Stat1 phosphorylation returned to basal level in chimeric mice treated with IFNg antibody, whereas the total Stat1 amounts were only partially diminished ( Figure 4C ). Elevated levels of TRAF6 and IRAK1 in miR-146a-deficient T cells were largely unaffected by IFNg antibody treatment and, thus, demonstrate the specificity of the observed effects of IFNg neutralization. 
Stat1
+/+ /Foxp3KO controls. As a result,
/Foxp3KO mice developed a much milder and delayed immune-mediated pathology ( Figure 4E ; data not shown). In agreement with a milder disease phenotype, we observed significantly reduced IFNg secretion by both miR146a-sufficient and -deficient effector CD4 + T cells. Furthermore, reduced Stat1 expression markedly diminished IFNg production by miR-146a-deficient Treg cells ( Figure 4F ). Interestingly, reduced IFNg production was accompanied by a substantial increase in IL-4 producing miR-146a-sufficient and -deficient effector CD4 + T cells in Mirn146a Figure 4G ). Together, these results provided genetic evidence that miR-146a ensures Treg cellmediated control of Th1 responses at least in part through targeting Stat1 and that limiting Stat1 expression in miR-146a-deficient Treg cells moderates these responses.
IFNg Production by miR-146a-Deficient T Cells Contributes to, but Does Not Fully Account for, Pathogenic Th1 Responses in Mirn146a
À/À /Foxp3KO Mice
The mixed bone marrow transfers using miR-146a-deficient hematopoietic stem cells revealed an important role for miR146a in Treg cells and suggested that miR-146a deficiency in these cells leads to Th1-mediated disease. However, we cannot formally exclude potential contribution to the disease by other miR-146a-deficient cell subsets in addition to Treg cells. In addition, the generation of miR-146a-deficient ''former'' Treg cells due to the loss of Foxp3 by some Treg cells upon adoptive transfer into lymphopenic hosts raises a question as to whether miR-146a deficiency in Treg cells could solely account for dysregulation of Th1 responses ( Figure S3A ). Since miR-146a deficiency resulted in a similar level of Stat1 upregulation and activation in both Treg and effector T cells ( Figures 4C and 4D) , it is plausible that IFNg production resulting from unrestrained Stat1 activation in miR-146a-deficient T effector cells contributed to the disease in chimeric mice harboring miR-146a-deficient Treg cells. Consistent with this possibility, we found that miR-146a-deficient T cells exhibited elevated IFNg, but not IL-4 production upon activation under nonpolarizing Th0 condition ( Figure 5A ).
To dissociate a role of miR-146a in Treg cell-mediated suppression from its role in restraining IFN-g production by T effector cells, we generated miR-146a-deficient mice lacking IFNg (Mirn146a
and Ly5.1 + Foxp3KO BM cells mixed at 1:1 ratio into Rag2-or TCRbd-deficient recipients ( Figure 5B ). These Mirn146a
/Foxp3KO mice allowed us to assess a role of miR-146a in Treg cell-mediated suppression of pathogenic Th1 responses without a confounding effect of the IFNg production by miR146a-deficient cells. We found that even in the absence of IFNg supplied by miR-146a-deficient cells, Mirn146a À/À Ifng À/À / Foxp3KO developed autoimmune disease accompanied by markedly augmented IFNg production by miR-146a-sufficient CD4 + and CD8 + T cells ( Figures 5C and 5D ). Consistent with the increased IFNg production, miR-146a-sufficient effector CD4 + T cells displayed an activated phenotype along with elevated CXCR3 expression ( Figure 5E ). These results provide further support for the notion that miR-146a plays an indispensable role in Treg cell-mediated Th1 regulation. Nevertheless, it must be noted that miR-146a-sufficient T cells from Mirn146a
Ifng
À/À /Foxp3KO mice produced less IFNg and were less activated in comparison to those from Mirn146a
/Foxp3KO mice. This observation suggested that IFNg production by miR-146a-deficient cells contributed to, but did not fully account for the development of severe Th1 pathology in the presence of miR-146a-deficient Treg cells ( Figures 5C and 5D) . Thus, miR-146a limits Th1 responses in two ways: by endowing Treg cells with the ability to suppress Th1 responses and by negatively regulating T effector cells in a cell-autonomous manner. Corresponding to this role in the Th1 response, we found higher levels of miR-146a in both T effector and Treg cells with Th1-like features (CXCR3 + T-bet hi )
in comparison to their CXCR3 -T-bet low counterparts ( Figures  5F-5I ).
Unrestrained Stat1 Activation in Treg Cells Results in IFNg-Mediated Th1 Pathology
Considering that each miRNA regulates multiple targets, it was important to examine the consequences of altering Stat1 activation in Treg cells by means other than the manipulation of miR146a expression. Therefore, we performed a ''gain-of-function'' experiment by analyzing mice with a Treg-specific ablation of SOCS1, a negative regulator of Stat1. Although SOCS1 also controls other signaling pathways, loss of SOCS1-dependent negative regulation of Stat1 is the major contributor to the IFNg-mediated immunopathology in mice with SOCS1 deficiency (Kubo et al., 2003; Alexander et al., 1999; Horino et al., 2008; Marine et al., 1999) . As shown in Figures 6A-6F , increased Treg cell numbers were observed in Foxp3
Cre
Socs1
fl/fl mice. This is likely due to augmented IL-2R/Stat5 signaling ( Figure S4 ; Zhan et al., 2009 ). However, despite this increase in Treg number, Foxp3 Cre Socs1 fl/fl mice showed clinical signs of immune-mediated pathology including conjunctivitis, blepharitis, and dermatitis by 6 weeks of age ( Figure 6G) Figure S5A ) exhibited an accelerated kinetics and increased severity of autoimmune disease in a close resemblance to Mirn146a À/À /Foxp3KO mice ( Figures  S5B-S5D) .
Together, our studies suggest that elevated miR-146a expression in Treg cells is required for control of IFNg-mediated Th1 immune responses at least in part through targeting Stat1, a key molecule in the IFNg signaling pathway. Our results further imply that excessive effector cytokine signaling in Treg cells may lead to their failure to suppress the corresponding response and consequently brings about severe autoimmunity. (Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008) . These mice, like Foxp3 null mice, which are genetically devoid of Treg cells, develop unprovoked Th1, Th2, and Th17 responses and die before 4 weeks of age from severe immune-mediated lesions in a variety of organs (Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008) . In an effort to identify specific miRNAs contributing to Treg function, we discovered that miR-155, whose elevated expression in Treg cells is driven by Foxp3, confers competitive fitness to Treg cells by increasing sensitivity of IL-2R signaling through targeting SOCS1. However, miR-155 was dispensable for suppressor function of Treg cells despite its nonredundant role in Treg homeostasis (Kohlhaas et al., 2009; . Another recent study suggested that high level of cAMP expression in Treg cells is conditional upon low amounts of miR-142-3p and that forced expression of this miRNA in Treg cells attenuates their ability to suppress T cell proliferation in vitro ). However, the striking loss of suppressor function observed in Dicer-deficient Treg cells is most likely due to loss of miRNAs that are overrepresented in these cells (Liston et al., 2008) . Here, we demonstrate an essential role for one miRNA, miR-146a, in Treg cell function in vivo by analyzing chimeric mice generated upon cotransfer of miR-146a-deficient and (Zheng et al., 2009) . Similarly, the expression of T-bet, another key transcription factor in Th1 effector cell differentiation, is induced in Treg cells in a Stat1-dependent manner in response to IFNg signaling and enables them to proliferate, migrate to, and accumulate at the sites of Th1 responses (Koch et al., 2009 ). Likewise, we have found that Treg cell-restricted ablation of Stat3, a transcription factor required for Th17 induction, leads to uncontrolled Th17-dependent pathology ). These studies suggest that in Treg cells distinct suppressor mechanisms are tailored to fit particular tissue and inflammatory settings by the same transcription factors which guide effector T cell differentiation in response to similar cues. In this study, we extended this concept to miRNAs by demonstrating that fatal immune-mediated lesions observed in the presence of miR-146a-deficient Treg cells were accompanied by sharply augmented Th1 responses and were dependent upon increased amounts of IFNg.
Activation of the transcription factor Stat1 downstream of the IFNg receptor facilitates differentiation of Th1 cells and forced expression of a Stat1-encoding transgene in T cells results in an IFNg-mediated immunopathology (Siebler et al., 2003) . A connection between miR-146a and Stat1, a key transcription factor in IFNg response, was suggested by two recent studies implying that Stat1 serves as a miR-146a target in human lymphocytes and monocytes (Cameron et al., 2008; Tang et al., 2009) . Despite the lack of a canonical miR-146a site in the 3 0 UTR of the mouse Stat1 gene, it contains a highly conserved site with partial complementarity to miR-146a seed sequence and additional complementarity in the adjacent sequence. Luciferase reporter assays demonstrated that this putative miR-146a binding site is crucial for miR-146a-mediated repression of Stat1. In addition, we have currently employed the HITS-CLIP (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation) approach to identify miR targets in T cells. Our preliminary data confirmed the proposed region for miR-146a binding in the mouse Stat1 gene (data not shown). More importantly, the disease observed in mice harboring miR-146a-deficient Treg cells was largely alleviated when miR-146a deficiency was coupled with Stat1 hemizygosity. Finally, important independent confirmation of (F and G) Frequency of (F) IFNg-or (G) IL-4-secreting cells in Foxp3 In addition to Stat1, miR-146a was previously shown to negatively regulate TLR/IL-1R signaling pathway in macrophages by targeting TRAF6 and IRAK1/2 (Hou et al., 2009; Taganov et al., 2006) . Indeed, levels TRAF6 and IRAK1 proteins were increased in both miR-146a-deficient Treg and non-Treg T cells. It has been shown that IL-1R signaling facilitates Th17 differentiation and IL-17 production (Chung et al., 2009; Maitra et al., 2009) . Furthermore, Th2 responses are also facilitated by signaling through IL-1R and IL-33R, another TRAF6/IRAK-dependent IL-1R family member (Ben-Sasson et al., 2009; Schmitz et al., 2005) . Thus, according to the idea of ''symmetry'' between cues eliciting effector T cell differentiation and corresponding suppressor capability in Treg cells, miR-146a deficiency in Treg cells could also result in augmented Th17 or Th2 responses. However, the lack of Th2 or Th17 cytokine production in mice harboring miR-146a-deficient Treg cells and the unimpeded ability of miR-146a-deficient Treg cells to suppress in vitro proliferative responses of T cells demonstrated that miR-146a deficiency in Treg cells results in a selective impairment in their ability to regulate Th1 responses. Lack of a detectable increase in Th2 and Th17 responses in the presence of miR-146a-deficient Treg cells can be explained by the fact that IFNg/Stat1 signaling, while promoting Th1 immune response, inhibits the differentiation of Th2 and Th17 cells (Hu and Ivashkiv, 2009 ). Thus, it is possible that the potential impact of dysregulated TRAF6/IRAK1 signaling in miR-146a-deficient Treg cells was masked by the dominant effect of elevated Stat1 expression and activation. In support of this idea, combined miR-146a deficiency and Stat1 hemizygosity in Treg cells resulted in an increase in IL-4 producing Th2 cells in addition to the aforementioned decrease in IFNgproducing Th1 cells.
Although the heightened Stat1 activation associated with miR-146a and SOCS1 deficiency in Treg cells impaired their ability to suppress Th1 responses, the numbers of miR-146a-and SOCS1-deficient Treg cells were markedly increased compared to their wild-type counterparts. Whereas an increase in size of SOCS1-deficient Treg subset is most likely a consequence of augmented IL-2R signaling and Stat5 phosphorylation , miR-146a deficiency did not alter Stat5 expression or activation (data not shown). In addition, miR-146a-deficient Treg cell number was not decreased by the attenuated Stat1 phosphorylation and inflammation that accompanied antibody-mediated blockade of IFNg signaling in chimeric mice, or Stat1 haploinsufficiency. These findings suggested that de-repression of miR-146a targets other than Stat1 likely contributed to the increased Treg cell numbers in miR-146a-deficient mice.
Our findings that miR-146a-or SOCS1-deficient Treg cells fail to control Th1 responses likely due to unrestrained expression and activation of Stat1 may appear to fit the aforementioned concept of ''symmetry'' in the integration of environmental cues by Treg and effector T cells. However, whereas in previous studies it was the lack of Th lineage-specific transcription factors Stat3, Irf4, and T-bet in Treg cells that resulted in impaired suppression of Th17, Th2, and Th1 responses, respectively, in this study unrestrained activation of Stat1 led to immunopathology. Importantly, Stat1 as well as IFNg receptor (IFNgR) expression in Treg cells are necessary for T-bet induction in Treg cells, a prerequisite for efficient suppression of Th1 responses (Koch et al., 2009 ). The observations that both the lack of Stat1 and unrestrained Stat1 activation resulted in a breakdown of immunologic tolerance suggested that Tregmediated suppression of Th1-mediated immunopathology is dependent upon a certain optimal range of Stat1 activation by cytokines. Moreover, by limiting Stat1 amounts in Treg cells, miR-146a prevents their deviation into IFNg-producing ''Th1-like'' cells and thereby, safeguards their function and identity in inflammatory settings. Our findings also raise a question as to why miR-146a-or SOCS1-deficient Treg cells fail to control Th1 responses. Chemokine receptor CXCR3, a well-characterized target of T-bet (Beima et al., 2006; Lord et al., 2005) , is induced in Treg cells in a T-bet-dependent manner and endows them with the ability to migrate to the sites of Th1 responses, a prerequisite for their efficient regulation (Koch et al., 2009 (Fontenot et al., 2003) , Foxp3 YFP-cre (Rubtsov et al., 2008) , SOCS1 fl , and Stat1 À/À (Meraz et al., 1996) mice were housed under SPF conditions. Disease development was monitored by frequent visual examination and histopathological analyses. All mice were used in accordance with guidelines from the Institutional Animal Care Committee of the Memorial Sloan-Kettering Cancer Center.
Quantitative PCR Analysis
Total RNA (including microRNA) was prepared from FACS purified cells using miRNeasy kit (QIAGEN). For detecting the miR-146a and miR-146b expression levels, Taqman ''stem-loop'' real-time RT-PCR was performed as demonstrated previously (Jazdzewski et al., 2008) . For measuring primary miR-146a and miR-146b, first strand complementary DNA was synthesized by using iScript cDNA synthesis kit (Bio-Rad) followed by real-time PCR analysis (SYBR green; Applied Biosystems).
Generation of Bone Marrow Chimeras Mice and In Vivo IFNg Neutralization
Mixed bone marrow chimeras were generated as described elsewhere ). In brief, T cell-depleted bone marrow cells from mice of indicated genotypes were mixed at 1:1 ratio and injected into T cell-deficient Rag2 À/À or in some cases Tcrb/Tcrd À/À irradiated (950 rads) hosts (3-5 3 10 6 total cells/recipient). Clinical signs, tissue histology, and the immune cell subset composition in the thymus and secondary lymphoid tissues were examined 6 weeks after BM transfer or when mice became moribund. In some experiments, mixed BM chimeras were administrated i.p. with 0.5 mg neutralizing IFNg antibody (clone XMG1.2) or isotype-matched control IgG weekly starting at 3 weeks after BM transfer.
In Vitro Suppression Assay
The ability of miR-146-deficient and -sufficient Treg cells to suppress proliferative responses of T cells was assessed in a standard in vitro suppression assay (Liston et al., 2008) . In brief, FACS purified 4 3 10 4 naive Ly5.1 
Flow Cytometry and Cytokine Secretion Assays
Cell surface staining and flow cytometric analysis of CD4, CD8, CD25, CD62L, CD103, GITR, ICOS, and CXCR3 (all eBioscience) expression were performed as described elsewhere (Fontenot et al., 2005) . Intracellular staining of Foxp3, IL-4, IFNg, CTLA-4 (all eBioscience), and Ki67 (BD Bioscience) were performed following fixation and permeabilization according to manufacturer's instructions.
To measure T cell cytokine production, 2 3 10 6 splenocytes were stimulated in 24-well plates with PMA (50 ng/ml) and ionomycin (250 ng/ml) in the presence of ''Golgi plug'' (BD Biosciences) for 5 hr at 37 C before staining.
Luciferase Reporter Assay CD4 + T cells isolated from Mirn146a À/À or Mirn146a +/+ mice were cultured in 12-well plates (1 3 10 6 cells/well) and transfected with psiCheck2 luciferase reporter plasmids (Promega) containing either wild-type or mutated Stat1 3 0 UTR using Amaxa mouse T cell nucleofector kit (Lonza, Basel, Switerland). Cells were harvested 24 hr later and luciferase activity was assessed using Dual-Luciferase Reporter Assay System (Promega) according to manufacturer's protocol.
Western Blot Analysis
Cell lysates from miR-146a-sufficient or -deficient Ly5. 
